Liquid biopsy for disease monitoring after anti‐CD19 chimeric antigen receptor T cell in diffuse large B‐cell lymphoma

OBJECTIVES: Chimeric antigen receptor T cells (CARTs) against CD19 antigen represent an effective therapy for relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL). There is no diagnostic test able to predict which patients with residual disease will relapse from those that will reach a delaye...

Descripción completa

Detalles Bibliográficos
Autores principales: Maluquer, Clara, Bellosillo, Beatriz, Mussetti, Alberto, Domingo‐Domènech, Eva, Parody, Rocío, Fernández‐Ibarrondo, Lierni, Velasco, Roser, Moreno‐González, Gabriel, Sanz, Gabriela, Cortés, Montserrat, Sureda, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176123/
https://www.ncbi.nlm.nih.gov/pubmed/35846093
http://dx.doi.org/10.1002/jha2.131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176123/
https://www.ncbi.nlm.nih.gov/pubmed/35846093
http://dx.doi.org/10.1002/jha2.131

Ejemplares similares